Journal
JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 357, Issue 1-2, Pages 106-108Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2015.07.007
Keywords
Multiple Sclerosis; Natalizumab therapy; HERV-Wenv; Epstein Barr Virus (EBV); Mycobacterium avium ss. paratuberculosis (MAP); Antibodies; ELISA
Categories
Funding
- Sardinian Region L.R. [CRP-25160]
- Fondazione Banco di Sardegna
- FISM Fondazione Italiana Sclerosi Multipla [Cod.2009/R/25]
Ask authors/readers for more resources
Multiple Sclerosis (MS) is a heterogeneous disorder of the central nervous system (CNS) that begins as an inflammatory autoimmune disorder mediated by auto-reactive lymphocyte followed by microglial activation and chronic degeneration. The etiology of Multiple Sclerosis (MS) is unknown but several data support the hypothesis of possible infectious agents which may act as a trigger for the pathogenic cascade. Human endogenous retrovirus (HERV-W/MSRV), Epstein Barr Virus (EBV) and Mycobacterium avium ss. paratuberculosis (MAP) have been associated to Multiple Sclerosis. In this study, we evaluated the humoral response against different peptides: the human endogenous retrovirus HERV-Wenv(73-88), MAP106c(121-132) from MAP, EBNA1 (400-413) from EBV and the homologous human peptide MBP85-98 in a cohort of MS patients treated with natalizumab. Results showed a statistically significant difference in the response against the HERV-W peptide in MS patients after two years of natalizumab treatment. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available